Shouvik Hazra

Shouvik Hazra has extensive experience in the pharmaceutical industry, holding key marketing roles at Abbott from May 2016 to the present, including Marketing Head and Group Product Manager for the CNS and Neuropsychiatry divisions, where significant achievements include managing an Anti-Epilepsy portfolio worth INR 40 Cr and leading the brand "LEVESAM" to a 12% growth rate. Prior to Abbott, Shouvik Hazra worked at Cipla from March 2008 to April 2016 as Group Product Manager for the Anti-Infectives portfolio, successfully establishing Colistin Therapy in India and launching the concept of Inhaled Antibiotics. Shouvik Hazra began the career as a Management Trainee at Cipla, focusing on corporate hospital sales. Educational qualifications include an MBA in Marketing and Finance from Shiva Institute of Management Studies and a BS in Chemistry from St. Paul's Cathedral Mission College, along with an Executive Management Program from SP Jain School of Global Management.